Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CS-8958 Clinical Pharmacology study - Safety and pharmacokinetics of nebulized laninamivir octanoate (CS-8958) after a single inhaled administration in healthy male Japanese subjects -

Next Previous
Trial Profile

CS-8958 Clinical Pharmacology study - Safety and pharmacokinetics of nebulized laninamivir octanoate (CS-8958) after a single inhaled administration in healthy male Japanese subjects -

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Laninamivir (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacokinetics
  • Sponsors Daiichi Sankyo Company

    • Most Recent Events

    • 23 Oct 2017 Results published in the Antimicrobial Agents and Chemotherapy
    • 27 Jun 2017 Results evaluating the the safety and pharmacokinetics of nebulized laninamivir octanoate and laninamivir in healthy male Japanese subjects, presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics.
    • 17 Jun 2016 Status changed from not yet recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top